ADVANCES IN DRUG RESISTANCE RESEARCH

ADVANCES IN DRUG RESISTANCE RESEARCH

Library of Congress Cataloging-in-Publication Data

Contents

Preface

Chapter 1: Mechanisms of Cisplatin Resistance: DNA Repairand Cellular Implications

Abstract

Introduction

Conclusion

References

Chapter 2: Multi-Drug Resistancein Cancer and New Approachesfor Its Overcoming

Abstract

Introduction

Role of Natural Productsin Overcoming MDR

Emerging Techniquesfor Overcoming MDR

Our Approaches for Overcoming MDR

Conclusion

References

Chapter 3: Tumor Fibroblasts:Pivotal Players in DrugResistance

Abstract

Challenges in Cancer Chemotherapy

Types and Origins of Tumor Fibroblasts

Tumor Fibroblasts Shape the Architecture of Chemoresistance

Tumor Fibroblasts-Derived SolubleFactors Confer to Increased TumorCell Survival

Tumor Fibroblasts Contributeto EMT Induction

Strategies to Overcome TumorFibroblasts-Mediated Chemoresistance

Conclusion

References

Chapter 4: Erythropoiesis Stimulating Agent Resistance

Abstract

Introduction

What is ESA Resistance?

Why is ESA ResistanceClinically Important?

What Causes ESA Resistance?

How Should ESA Resistance Be Managed?

Conclusion

References

Chapter 5: Therapeutic Optionsfor Metastatic CastrationResistant Prostate Cancer:Has the Situation Improved?

Abstract

Introduction

Conclusion

References

Chapter 6: Current Trends in ProstateCancer Treatmentand Drug Resistance

Abstract

Introduction

Drugs That Target Androgen-Signalling

Conclusion

References

Chapter 7: Resistance of Metastatic RenalCell Carcinomas to Chemoand Immunotherapy:Clinicians’ Perspective

Abstract

Introduction

Surgical Management of Localised RCC

Surgical Management of Advanced RCC

Non-Surgical Managementof Metastatic RCC

Resistance to Radiotherapy

Resistance to Hormonal Therapy

Resistance to Chemotherapy

Molecular Mechanismsof Chemotherapy Resistance

Multi-Drug Resistance Molecules

Resistance to Apoptosis

Hyperproliferation

Recent Advances in OvercomingChemotherapy Resistance

Immunotherapy

Conclusion

References

Chapter 8: Resistance of Renal CellCarcinoma to Targeted Therapy

Abstract

Introduction

Mammalian Target of Rapamycin(MTOR) Inhibitors

Resistance to Targeted Therapy

Alternative Pro-Angiogenic Pathwaysin Drug Resistance

Inadequate Target Inhibitionand Resistance to Therapy

Therapy-Mediated VEGF Up-Regulationin Drug Resistance

Faulty Mammalian Target of Rapamycin(MTOR) Pathway in Drug Resistance

Advances in Overcoming Resistanceto Targeted Therapy

Future Directions

Conclusion

References

Chapter 9: Molecular Mechanismsof Sunitinib Resistancein Renal Cell Carcinoma

Abstract

Introduction

Sphingosine Kinase-1

P53, HDM2 AND HDMX

Cycloxygenase-2

Akt and p44/42 MAPKSignalling Pathways

Micro RNA

EMMPRIN

PTEN AKT/mTOR

PRKX

Lysosomal Sequestration

Angiostatic Signaling

IL-8

RLIP76

Epithelial Mesenchymal Transition

Genetic Polymorphisms

Conclusion

References

About the Editor

Index